BACKGROUND: We have recently reported from Epilymph, a multicentre case-control study of lymphoma conducted in six European countries, a significant association between NHL and self-reported history of past or present HBV infection based on questionnaire data from face-to-face interviews. METHODS: To corroborate this observation, we used the data and blood specimen from Epilymph to investigate the associations between serological indicators of HBV infection with risk of Hodgkin lymphoma, non-Hodgkin lymphoma (NHL) and specific lymphoma entities. For 1,518 cases and 1,496 controls with sufficient amount of serum or plasma, we tested HBs-antigen, anti-HBc and anti-HBs to distinguish between current or past infection and immunity by vaccination. Statistical analysis was carried out with unconditional logistic regression. RESULTS: We found a positive association of a past HBV infection with multiple myeloma (MM, OR = 1.97, 95 % CL = 1.16-3.37). Non-significant associations were found between past HBV infection and B-cell chronic lymphocytic leukaemia (B-CLL, OR = 1.33, 95 % CL = 0.82-2.16) and T-cell NHL (OR = 1.59, 95 % CL = 0.65-3.90), as well as between current HBV infection and NHL (OR = 1.49, 95 % CL = 0.65-3.41), B-NHL (OR = 1.58, 95 % CL = 0.69-3.64) and diffuse large B-cell lymphoma (DLBCL, OR = 1.50, 95 % CL = 0.47-4.82). Subjects having self-reported HBV infection were serological positive in 75 % of cases and 80 % of controls. For vaccination, the corresponding figures were 49 and 54 %, respectively. CONCLUSION: The present results support previous reports of an association between a history of HBV infection with an elevated lymphoma risk and add multiple myeloma to the list of potentially virus-associated lymphoma entities.
BACKGROUND: We have recently reported from Epilymph, a multicentre case-control study of lymphoma conducted in six European countries, a significant association between NHL and self-reported history of past or present HBV infection based on questionnaire data from face-to-face interviews. METHODS: To corroborate this observation, we used the data and blood specimen from Epilymph to investigate the associations between serological indicators of HBV infection with risk of Hodgkin lymphoma, non-Hodgkin lymphoma (NHL) and specific lymphoma entities. For 1,518 cases and 1,496 controls with sufficient amount of serum or plasma, we tested HBs-antigen, anti-HBc and anti-HBs to distinguish between current or past infection and immunity by vaccination. Statistical analysis was carried out with unconditional logistic regression. RESULTS: We found a positive association of a past HBV infection with multiple myeloma (MM, OR = 1.97, 95 % CL = 1.16-3.37). Non-significant associations were found between past HBV infection and B-cell chronic lymphocytic leukaemia (B-CLL, OR = 1.33, 95 % CL = 0.82-2.16) and T-cell NHL (OR = 1.59, 95 % CL = 0.65-3.90), as well as between current HBV infection and NHL (OR = 1.49, 95 % CL = 0.65-3.41), B-NHL (OR = 1.58, 95 % CL = 0.69-3.64) and diffuse large B-cell lymphoma (DLBCL, OR = 1.50, 95 % CL = 0.47-4.82). Subjects having self-reported HBV infection were serological positive in 75 % of cases and 80 % of controls. For vaccination, the corresponding figures were 49 and 54 %, respectively. CONCLUSION: The present results support previous reports of an association between a history of HBV infection with an elevated lymphoma risk and add multiple myeloma to the list of potentially virus-associated lymphoma entities.
Authors: M Kuniyoshi; M Nakamuta; H Sakai; M Enjoji; N Kinukawa; K Kotoh; M Fukutomi; M Yokota; H Nishi; H Iwamoto; N Uike; J Nishimura; S Inaba; Y Maeda; H Nawata; K Muta Journal: J Gastroenterol Hepatol Date: 2001-02 Impact factor: 4.029
Authors: Silvia de Sanjose; Yolanda Benavente; Claire M Vajdic; Eric A Engels; Lindsay M Morton; Paige M Bracci; John J Spinelli; Tongzhang Zheng; Yawei Zhang; Silvia Franceschi; Renato Talamini; Elizabeth A Holly; Andrew E Grulich; James R Cerhan; Patricia Hartge; Wendy Cozen; Paolo Boffetta; Paul Brennan; Marc Maynadié; Pierluigi Cocco; Ramon Bosch; Lenka Foretova; Anthony Staines; Nikolaus Becker; Alexandra Nieters Journal: Clin Gastroenterol Hepatol Date: 2008-04 Impact factor: 11.382
Authors: Herve Besson; Paul Brennan; Nikolaus Becker; Alexandra Nieters; Silvia De Sanjosé; Rebeca Font; Marc Maynadié; Lenka Foretova; Pierluigi L Cocco; Anthony Staines; Martine Vornanen; Paolo Boffetta Journal: Int J Cancer Date: 2006-08-15 Impact factor: 7.396
Authors: Gerald Y Minuk; Betty Lerner; Spencer B Gibson; James B Johnston; Julia Uhanova; Anton Andonov; Jun Wu Journal: Can J Gastroenterol Hepatol Date: 2014-03
Authors: Lindsay M Morton; Todd M Gibson; Christina A Clarke; Charles F Lynch; Dennis D Weisenburger; Eric A Engels Journal: Haematologica Date: 2014-02-21 Impact factor: 11.047
Authors: Z Lee; S Nishikawa; S Gao; J B Eksteen; M Czub; M J Gill; C Osiowy; F van der Meer; G van Marle; C S Coffin Journal: PLoS One Date: 2015-09-21 Impact factor: 3.240
Authors: N Mansouri; A Movafagh; A Sayad; S Ghafouri-Fard; H Darvish; D Zare-Abdollahi; B Emamalizadeh; F Shahvaisizadeh; H Ghaedi; M Bastami; M Kayyal; M Hashemi; Mh Heidari; A Nejatizadeh; M Zamani Journal: Iran J Ped Hematol Oncol Date: 2014-12-10
Authors: Martina Taborelli; Jerry Polesel; Maurizio Montella; Massimo Libra; Rosamaria Tedeschi; Monica Battiston; Michele Spina; Francesco Di Raimondo; Antonio Pinto; Anna Crispo; Maria Grimaldi; Silvia Franceschi; Luigino Dal Maso; Diego Serraino Journal: Infect Agent Cancer Date: 2016-06-23 Impact factor: 2.965